User login
Dr Jack West, from City of Hope Comprehensive Cancer Center, Duarte, California, gives his picks of noteworthy advances in non–small cell lung cancer (NSCLC) presented at the 37th Annual Meeting of the Society for Immunotherapy of Cancer.
Dr West starts by discussing data from a real-world analysis of patients who had undergone next-generation sequencing and received a variety of treatments. This revealed that those with KRAS mutations, alongside STK11 and KEAP1 mutations, had worse outcomes.
Next, he reports on a genomic study indicating that acquired resistance mechanisms affecting a range of genes were unique to immunotherapy and were not seen with chemotherapy or targeted therapies.
Dr West moves on to KEYNOTE-495, which found that NSCLC patients with a favorable gene expression profile and low tumor mutational burden had the greatest response to combination therapy with pembrolizumab and lenvatinib.
The LAG-3 inhibitor eftilagimod alpha in combination with pembrolizumab was examined in the next study, which showed that PD-L1 expression was related to response rates.
Dr West closes by discussing a talk that made the case for neoadjuvant over adjuvant immunotherapy in lung cancer and other settings.
--
Associate Professor, Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, California; Vice President, Network Strategy, AccessHope, Los Angeles, California
H. Jack West, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Amgen; AstraZeneca; Genentech/Roche; Merck; Mirati; Regeneron; Takeda
Serve(d) as a speaker or a member of a speakers bureau for: Amgen; AstraZeneca; Merck
Dr Jack West, from City of Hope Comprehensive Cancer Center, Duarte, California, gives his picks of noteworthy advances in non–small cell lung cancer (NSCLC) presented at the 37th Annual Meeting of the Society for Immunotherapy of Cancer.
Dr West starts by discussing data from a real-world analysis of patients who had undergone next-generation sequencing and received a variety of treatments. This revealed that those with KRAS mutations, alongside STK11 and KEAP1 mutations, had worse outcomes.
Next, he reports on a genomic study indicating that acquired resistance mechanisms affecting a range of genes were unique to immunotherapy and were not seen with chemotherapy or targeted therapies.
Dr West moves on to KEYNOTE-495, which found that NSCLC patients with a favorable gene expression profile and low tumor mutational burden had the greatest response to combination therapy with pembrolizumab and lenvatinib.
The LAG-3 inhibitor eftilagimod alpha in combination with pembrolizumab was examined in the next study, which showed that PD-L1 expression was related to response rates.
Dr West closes by discussing a talk that made the case for neoadjuvant over adjuvant immunotherapy in lung cancer and other settings.
--
Associate Professor, Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, California; Vice President, Network Strategy, AccessHope, Los Angeles, California
H. Jack West, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Amgen; AstraZeneca; Genentech/Roche; Merck; Mirati; Regeneron; Takeda
Serve(d) as a speaker or a member of a speakers bureau for: Amgen; AstraZeneca; Merck
Dr Jack West, from City of Hope Comprehensive Cancer Center, Duarte, California, gives his picks of noteworthy advances in non–small cell lung cancer (NSCLC) presented at the 37th Annual Meeting of the Society for Immunotherapy of Cancer.
Dr West starts by discussing data from a real-world analysis of patients who had undergone next-generation sequencing and received a variety of treatments. This revealed that those with KRAS mutations, alongside STK11 and KEAP1 mutations, had worse outcomes.
Next, he reports on a genomic study indicating that acquired resistance mechanisms affecting a range of genes were unique to immunotherapy and were not seen with chemotherapy or targeted therapies.
Dr West moves on to KEYNOTE-495, which found that NSCLC patients with a favorable gene expression profile and low tumor mutational burden had the greatest response to combination therapy with pembrolizumab and lenvatinib.
The LAG-3 inhibitor eftilagimod alpha in combination with pembrolizumab was examined in the next study, which showed that PD-L1 expression was related to response rates.
Dr West closes by discussing a talk that made the case for neoadjuvant over adjuvant immunotherapy in lung cancer and other settings.
--
Associate Professor, Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, California; Vice President, Network Strategy, AccessHope, Los Angeles, California
H. Jack West, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Amgen; AstraZeneca; Genentech/Roche; Merck; Mirati; Regeneron; Takeda
Serve(d) as a speaker or a member of a speakers bureau for: Amgen; AstraZeneca; Merck
